Abstract: The current invention reports a method for purifying an antibody by reducing the content of a host cell protein. The method employs a wash step with a low conductivity aqueous solution in an affinity chromatography.

Abstract: The present invention relates to antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations, and methods of using the same.

Abstract: The present invention provides compounds of formula (I) CB(I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.

Abstract: The invention comprises radiolabeled MOEM type oligonucleotide of the formula (I), (I) wherein n, X1, X2, the linker (1), the linker (2), Q* and the receptor targeting moiety are as defined (I) the description. The radiolabeled oligonucleotides of the formula (I) can be used for the determination of the biodistribution and pharmacokinetics of the oligonucleotide in the tissue or body fluid.

Abstract: The invention relates to a process for the preparation of a fatty acid compound of the formula Ia wherein AEEAc stands for 2-(2-(2-aminoethoxy) ethoxy) acetic acid and PROT1 is an ester protecting group and to the use of the fatty acid compound of the formula Ia for the preparation of peptides.

Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

Abstract: Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody.

Abstract: The present invention relates to anti-CD3/anti-CD28 bispecific antigen binding molecules and masked protease activated forms thereof, methods for their production, pharmaceutical compositions containing these molecules, and their use as immunomodulators and/or costiumulators in the treatment of cancer.

Abstract: The invention relates to 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to PD-L1 and their use in the treatment of cancer.

Abstract: The method includes, for each of a plurality of tiles of an image, extracting a feature vector from the tile; providing a Multiple-Instance-Learning program configured to use a model for classifying any input image as a member of one out of at least two different classes based on feature vectors extracted from the tiles; for each of the tiles, computing a certainty value indicating the certainty of the model regarding the contribution of the tile's feature vector on the classification of the image; for each of the images, using, by the MIL-program, a certainty-value-based pooling function for aggregating the feature vectors of the image or predictive values computed from the feature vectors of the image into an aggregated predictive value as a function of the certainty values of the tiles; and classifying each of the images as a member of one of the classes based on the aggregated predictive value.

Abstract: The present invention relates to a new process for the preparation of (3R)-3-fluoropyrrolidine hydrochloride or an acceptable salts thereof via a N-Boc-(3S)-3-hydroxypyrrolidine intermediate. The process is suitable for the synthesis of N-Boc-(3S)-3-hydroxypyrrolidine at technical scale in high, not less than 99.85%-a/a optical purity and a purity of not less than 99.8%-a/a. The high quality N-Boc-(3S)-3-hydroxypyrrolidine can be converted to (3R)-3-fluoropyrrolidine hydrochloride exhibiting an optical purity of not less than 99.95%-a/a and a purity of not less than 99.5%-a/a thus making it a suitable intermediate for manufacturing of pharmaceutical active compounds.

Abstract: Described herein are the mono hydrochloric acid salt, as well as the free zwitterion of the macrocyclic peptide antibiotic 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid. Also described are amorphous and crystalline forms of said hydrochloric acid salt and free zwitterion, as well as methods of making the same and methods of using the same in medical therapy.

Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2, X3 and W are as described herein, composition including the compounds and methods of using the compounds.

Abstract: The invention provides compounds having the general formula (I) wherein A, L, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: Provided are oligonucleotides that increase the expression of glucocerebrosidase (GBA) in cells; conjugates, salts and pharmaceutical compositions thereof; and methods for treatment of diseases associated with reduced expression of GBA, including Gaucher's disease and/or Parkinson's disease. The oligonucleotides may comprise a contiguous sequence complementary to contiguous bases in the 3? untranslated region (UTR) of the GBA mRNA transcript.

Abstract: A computer-implemented method of identifying a tissue type in digital histological images of human or animal tissue comprises training a convolutional neural network (CNN) to identify a particular target tissue type in a plurality of training data sets of digital histological images, inputting a test data set of digital histological images into the trained CNN, and receiving as an output result of the CNN a probability value that the inputted test data set corresponds to the target tissue type. A training procedure of the CNN comprises performing with training data sets: selecting a target tissue area of the training data set, dividing the target tissue area into different sets of tiles of constant size but having different image magnifications, and inputting the sets of tiles into a multi-headed CNN, wherein the sets of tiles having different image magnifications are processed in parallel and the features of the sets of tiles are concatenated.

Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (“Compound A, A-S, or A-R”), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.